StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Free Report) in a research report released on Monday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Brooklyn ImmunoTherapeutics stock traded up $0.11 during trading hours on Monday, reaching $6.01. 425,767 shares of the stock were exchanged, compared to its average volume of 828,208. The stock has a market cap of $353.54 million, a P/E ratio of -2.65 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $5.10 and a 52-week high of $8.31. The firm's 50 day moving average is $5.19 and its 200 day moving average is $2.22.

Brooklyn ImmunoTherapeutics Announces Dividend

The firm also recently announced a monthly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, March 14th were paid a dividend of $0.0862 per share. This represents a $1.03 dividend on an annualized basis and a dividend yield of 17.20%. The ex-dividend date of this dividend was Friday, March 14th. Brooklyn ImmunoTherapeutics's dividend payout ratio (DPR) is -38.33%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.